Results 201 to 210 of about 48,363 (248)

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study. [PDF]

Front Endocrinol (Lausanne)
Wu JY, Lin YM, Hsu WH, Liu T, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC.   +8 more
europepmc   +1 more source

Future prospects of antiviral research in traditional Chinese medicine. [PDF]

Chin Herb Med
Wang K, Yang Z.
europepmc   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co-opting tumors in colorectal cancer liver metastases. [PDF]

FEBS J
Gantz A, Kapelanski-Lamoureux A, Rada M, Krzywon L, Tsamchoe M, Tsatoumas A, Petrillo SK, Seidah NG, Lazaris A, Metrakos P.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Proprotein convertase subtilisin/kexin type 9 inhibition

Current Opinion in Lipidology, 2012
There are now ample data that demonstrate that inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) can safely lower LDL cholesterol synergistically with statins. Considering that PCSK9 was first identified less than a decade ago, the last few years have shown rapid and remarkable advancements in our understanding and knowledge of the ...
David A, Marais, Dirk J, Blom, Francine, Petrides, Yann, Gouëffic, Gilles, Lambert   +4 more
openaire   +2 more sources

Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review

Combinatorial Chemistry & High Throughput Screening, 2023
Abstract: PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that helps to reduce cardiovascular events. This clinical result is attributable primarily to the crucial involvement of PCSK9 in regulating the low-density lipoprotein cholesterol level.
Sonia Singh, Himanshu Sharma, Raghavan Ramankutty, Sarada Ramaswamy, Nitin Agrawal   +4 more
openaire   +2 more sources

Proprotein convertase subtilisin/kexin type 9

Current Opinion in Cardiology, 2018
This review describes the pivotal role of genetic insights and technologies in the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rapid development of PCSK9 inhibitors - a revolutionary new class of lipid-lowering agents.PCSK9 was discovered as a the third gene implicated in familial hypercholesterolemia. Population genetics
Robert M, Stoekenbroek, John J P, Kastelein   +1 more
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism

2020
Plasma levels of cholesterol, especially low-density lipoprotein cholesterol (LDL-C), are positively correlated with the risk of cardiovascular disease. Buildup of LDL in the intima promotes the formation of foam cells and consequently initiates atherosclerosis, one of the main underlying causes of cardiovascular disease. Hepatic LDL receptor (LDLR) is
Shoudong, Guo, Xiao-Dan, Xia, Hong-Mei, Gu, Da-Wei, Zhang   +3 more
openaire   +2 more sources